摘要
目的:建立黄连不同炮制品及不同组分中6种生物碱含量测定的方法,同时以秀丽隐杆线虫let-60(n1046gf)为模型研究不同炮制品及组分的抗肿瘤活性。方法:对黄连不同炮制品及组分进行了6种生物碱(药根碱、非洲防己碱、表小檗碱、黄连碱、巴马汀、小檗碱)含量测定和抗肿瘤活性试验。结果:黄连不同种炮制品均可抑制线虫MUV表型,其中萸黄连和清炒黄连作用稍弱于黄连生品水提物;黄连大孔树脂分离的6个组分中,10%和30%乙醇组分可以显著降低线虫的MUV表型。结论:该实验建立了准确、稳定、全面的黄连生物碱含量测定方法和以秀丽隐杆线虫为模型的,简单、可靠、快速的抗肿瘤活性评价方法。
Objective: To establish a method for determination of 6 alkaloids of Rhizoma Coptidis in different processed products and components, and Caenorhabditis elegans(C.elegans) as a model to study the different processed products and components of anti-tumor activity. Methods: The content of 6 alkaloids(jateorhizine, columbamine, epiberine, eoptisine,palmatine, berberine) and antitumor activity in different processed products and components of Rhizoma Coptidis were studied.Results: The experimental results show that different kinds of processed products of Rhizoma Coptidis could inhibit the C.elegans Muv phenotype, including Yu Coptis and fried Coptis effect weaker than Rhizoma Coptidis water extract; in 6 groups of Rhizoma Coptidis macroporous resin separation, 10% and 30% ethanol groups can significantly reduce the C.elegans Muv phenotype.Conclusion: The experiment established an accurate, stable and comprehensive method for the determination of alkaloids in Rhizoma Coptidis and a simple, reliable and rapid anti-tumor activity evaluation method based on C.elegans.
引文
[1]国家药典委员会.中华人民共和国药典.一部.北京:中国医药科技出版社2015:303-305
[2]蒋俊,贾晓斌,薛璟,等.黄连的炮制历史沿革及其炮制品现代研究进展.中国医院药学杂志,2010,30(2):156-158
[3]张永鑫,刘晓,杨欣文,等.黄连4种饮片特征图谱研究及生物碱含量测定.药物分析杂志,2012,32(11):1957-1961
[4]卿大双,罗维早,孙建彬,等.一测多评法测定黄连及其炮制品中6种生物碱.中草药,2016,47(2):324-329
[5]张月月,王君明,崔瑛,等.中药生物碱类成分抗焦虑或抑郁活性及黄连生物碱药理作用研究进展.中华中医药杂志,2015,30(4):1184-1187
[6]吴鹏,王亚东,蒋怀周,等.小檗碱对铜负荷大鼠肝纤维化组织Notch信号通路的作用研究.中华中医药杂志,2018,33(10):4731-4735
[7]王亚,杨军辉,芮天奇,等.酒炙前后对上焦病症及肝脏能量代谢酶活性的影响.南京中医药大学学报,2014,30(4):335-339
[8]李佳川,孟宪丽,赖先荣,等.基于3T3-L1细胞的不同黄连炮制品“止消渴”药效比较研究.中药药理与临床,2010,26(2):52-54
[9]孙莹莹,钟凌云,龚千锋.基于大鼠舌体表面扫描电镜探讨黄连及其炮制品寒热药性.中药药理与临床,2011,27(1):54-55
[10]S Brenner.The Genetics of Caenorhabditis elegans.Genetics,1974,77(1):71-94
[11]Corsi A K,Wightman B,Chalfie M.A Transparent window into biology:A primer on Caenorhabditis elegans.Wormbook,2015:1-31
[12]Oreilly L P,Luke C J,Perlmutter D H,et al.C. elegans in highthroughput drug discovery.Adv Drug Deliver Rev,2014,69-70:247-253
[13]Markaki Maria,Tavernarakis,Nektarios.Modeling human diseases in Caenorhabditis elegans.Biotech Journal,2010,5(12):1261-1276
[14]Bos J L.Ras oncogenes in human cancer:A Review.Cancer Res,1989,49(17):4682-4689
[15]Han M,Sternberg P W.let-60,a Gene that specifies cell fates during C.elegans vulval induction,encodes a ras protein.Cell,1990,63(5):921-931
[16]Sundaram M V.RTK/Ras/MAPK signaling.Wormbook,2006:1-19
[17]Bae Y K,Sung J Y,Kim Y N,et al.An in vivo C.elegans model system for screening EGFR inhibiting anti-cancer drugs.PLOS ONE, 2012,7(9):42441